Literature DB >> 16364754

New viral vaccines.

Ann M Arvin, Harry B Greenberg.   

Abstract

Vaccination is the most effective medical intervention against diseases caused by human viral pathogens. Viral vaccines prevent or modify the severity of illness in the individual and interrupt or reduce the transmission of the pathogens to other susceptible people. Through these mechanisms, vaccines against smallpox, polio, measles and hepatitis B have had an enormous impact on world health over the last 50 years. Advances in basic virology and understanding of human immunity promise more progress in the control of human viral diseases as the 21st century begins. Some important targets, including human immunodeficiency virus, respiratory syncytial virus and hepatitis C virus present challenges that require more basic research. The purpose of this review is to highlight four new viral vaccines that have recently, or will soon demonstrate the effective translation of basic investigations into clinical benefits for disease control in healthy and high-risk populations. These vaccines include the live attenuated vaccines against the RNA viruses, rotavirus and influenza A and B, and vaccines against human papilloma virus and varicella-zoster virus, which are DNA viruses that cause morbidity and mortality through their capacity to establish persistent infection. Although only the influenza vaccine has been licensed in the United States, these other new tools for disease prevention are likely to be introduced within the next few years, with profound effects on the diseases that they cause. Hence, as Virology celebrates its 50th anniversary, it is appropriate to examine these examples of recent advances in viral vaccines.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16364754     DOI: 10.1016/j.virol.2005.09.057

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  16 in total

1.  Construction of HCV-polytope vaccine candidates harbouring immune-enhancer sequences and primary evaluation of their immunogenicity in BALB/c mice.

Authors:  Arash Arashkia; Farzin Roohvand; Arash Memarnejadian; Mohammad Reza Aghasadeghi; Sima Rafati
Journal:  Virus Genes       Date:  2009-10-31       Impact factor: 2.332

2.  Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates.

Authors:  Jason S Richardson; Stéphane Pillet; Alexander J Bello; Gary P Kobinger
Journal:  J Virol       Date:  2013-01-09       Impact factor: 5.103

3.  Vaccination with dendritic cells pulsed with hepatitis C pseudo particles induces specific immune responses in mice.

Authors:  Kilian Weigand; Franziska Voigt; Jens Encke; Birgit Hoyler; Wolfgang Stremmel; Christoph Eisenbach
Journal:  World J Gastroenterol       Date:  2012-02-28       Impact factor: 5.742

4.  Conformation-specific antibodies targeting the trimer-of-hairpins motif of the human T-cell leukemia virus type 1 transmembrane glycoprotein recognize the viral envelope but fail to neutralize viral entry.

Authors:  Antonis Mirsaliotis; Kulpash Nurkiyanova; Daniel Lamb; Jenny M Woof; David W Brighty
Journal:  J Virol       Date:  2007-03-21       Impact factor: 5.103

Review 5.  Rationalizing the development of live attenuated virus vaccines.

Authors:  Adam S Lauring; Jeremy O Jones; Raul Andino
Journal:  Nat Biotechnol       Date:  2010-06-07       Impact factor: 54.908

6.  Tolerability of two sequential electroporation treatments using MedPulser DNA delivery system (DDS) in healthy adults.

Authors:  Mark Wallace; Barbara Evans; Sandra Woods; Robin Mogg; Lei Zhang; Adam C Finnefrock; Dietmar Rabussay; Michael Fons; John Mallee; Devan Mehrotra; Florian Schödel; Luwy Musey
Journal:  Mol Ther       Date:  2009-03-10       Impact factor: 11.454

7.  A new polymorphism in the GRP78 is not associated with HBV invasion.

Authors:  Xiao Zhu; Yi Wang; Tao Tao; Dong-Pei Li; Fei-Fei Lan; Wei Zhu; Dan Xie; Hsiang-Fu Kung
Journal:  World J Gastroenterol       Date:  2009-10-21       Impact factor: 5.742

Review 8.  Treatment of hepatitis C virus infection.

Authors:  Kilian Weigand; Wolfgang Stremmel; Jens Encke
Journal:  World J Gastroenterol       Date:  2007-04-07       Impact factor: 5.742

9.  IRF3 inhibition by rotavirus NSP1 is host cell and virus strain dependent but independent of NSP1 proteasomal degradation.

Authors:  Adrish Sen; Ningguo Feng; Khalil Ettayebi; Michele E Hardy; Harry B Greenberg
Journal:  J Virol       Date:  2009-08-05       Impact factor: 5.103

10.  Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infections.

Authors:  Xiaoyan Zhan; Karen S Slobod; Sateesh Krishnamurthy; Laura E Luque; Toru Takimoto; Bart Jones; Sherri Surman; Charles J Russell; Allen Portner; Julia L Hurwitz
Journal:  Vaccine       Date:  2008-05-01       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.